Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What impact do you think this claim will have on the value of Libigel?
32. The method according to claim 28, wherein the decrease in the risk of a cardiovascular event in the treated women compared to the risk of cardiovascular events in untreated women is at least 70%.
Patent application title: Methods for decreasing cardiovascular risk in postmenopausal women
If the February 14 conference trumps both a Bio-t-gel PDUFA approval and a statement in relation this patent application. Expect very big movement on the share price.
When BPAX was floating around $0.50, analyst had a 1 yr target of $0.70 Now that analyst are predicting a 1 yr target of $2.85, wouldn't this mean that they believe BPAX present day value is approx. $2.00/share.
I find it interesting that not one analyst has ever recommended selling BPAX. Hold, Buy and Strong Buy, yes. But not one Sell.
This in itself speaks volumes.
Sorry Rustler, got to go with Nutsyprofessor on this one. I have kept tabs on everything, the Professor, Jeff and the intelligent non-spamming posters have contributed since that fateful day in December. It is worth reading to understand why Libigel is not only viable but probable.
If one takes a good looks at Biosante's pipeline, and it's diversity. Other then the lack of a marketing arm. Biosante has the foundation for becoming a Large Cap dividend paying company. Obviously a lot has to go in their favor for this to happen but I can honestly see Biosante with a $10+ billion Market Cap in as little as 10 years.
BioSante Pharmaceuticals, Inc., founded in 1996
BioSante bought Cell Genesys in 2009.
Thanks for the info. I am hoping that an informed day trader will see the value of sticking this one out.
I am a big fan of the insightful post that you Jeffqdh and the others have provided over at Yahoo. I really like the way you all feed off each other to get to the truth. Keep up the good work.
Please explain to me why many investors ignore the Cancer Research value of BIOSANTE. This link lays it out pretty well.
Cancer Vaccine
I took the time to look at a number of biotech companies focusing strictly on cancer research. Unless I am missing something the cancer research portion of the company alone should be worth over $1.50 /share.
Definitely the Rodney Dangerfield of the industry. NO RESPECT!
Hi 1955, since BPAX has a number of catalyst that will impact PPS. I am looking at dividing it to three parts - 1/3 third out before February 14th (Bio-T-Gel PDUFA) , 1/3 out by June (prior to safety trial results are released) and keep 1/3 third in for the ride through the safety trials.
I won't maximize possible returns but I won't regret getting totally out at the wrong time.
Long term I can see myself re-investing for the GVAX play.
Hope the suggestion helps.
Has anyone ever broken down the value of Biosante as two separate companies? A cancer research company and identify it's value and the everything else company including Elestrin, Bio-T-Gel, Libigel, The Pill-plus, Bio-Look etc...
It would be interesting to see what the sum of its parts adds up to in comparison to its competition.
Questions for Biosante
FYI
These are the questions being posed by the Nutsyprofessor of Yahoo board to the company.
Jeff, here are my final questions. Note that I also revised the efficacy data from the Safety trial question as well. The more important question is really with regards to what the FDA can or is willing to do and not necessarily what BioSante can do.
1) Can the FDA use efficacy data from the Safety trial if it chooses?
2) Given that LibiGel was specifically developed for women w/HSDD, why did the BLOOM trials include women with and w/out HSDD? Did BioSante specifically stratify non-FSD women to ensure equal distribution across both the LibiGel and placebo arms?
3) With regards to question #2, if this was an FDA SPA requirement, was there any concerns that the non-FSD women could throw off the efficacy results; especially due to higher variability in the average # of SSE's of non-FSD women? If so, was there any discussions about a solution to get around this issue?
4) With regards to the current LibiGel extension trial (NCT01235754); when does BioSante anticipate having results?
5) It is known that testosterone levels drop back to baseline levels within 24 hrs after stopping testosterone treatment, so what is the real purpose of this 12-week extension trial? Meaning, why would BioSante want to evaluate the persistence of benefit of LibiGel if testosterone levels are back to baseline levels?
6) The BioSante 2011 10K filing indicates that there is an SPA for naturally-induced menopause indication; how and when does BioSante intend on obtaining efficacy data for the naturally-induced menopausal indication?
Jeff, please send these to Mr. Doomberg as written and let's see if he responds. I don't really have high hopes that he would directly answer these questions.
Thanks
Hope he gets a response of value. Regardless,I will keep you all posted.
LESCO, now that I have apologized, can you answer the question I originally asked?
Why would you invest in any of the other companies. I listed, over BPAX?
Based on my findings BPAX is valued at 25% of where it should be.
Please enlighten me. If you apply the same undervaluation to the other companies I have listed, they all end up with Market Caps of $1 to $2 billion.
On the other hand if you shorted BPAX, I can see why you would be upset with me and my posts.
Hello puregambling, thought this might simply your research on the quality discussion threads on Yahoos board. I posted it for our BPAX board. It was current on the day it was posted. It will filter a lot of the crap and spam on Yahoo for you.
Nutsyprofessor posts
Hope it helps.
Note: look at the names that are involved in the discussions and look at their posts as well from the Jan 14th the date of my last link.
Have fun reading the very compelling information.
17 reasons why BPAX should open above a $1
I have taken the time to provide the links to the products and pipelines of the below noted companies along with their market cap (in $ million).
Look at this.
Biosante Pipeline $70.69 m
Biosnate \cancer \vaccine pipeline
Now look at these.
Myrexis Development Pipeline $72.46 m
Acadia Pharma pipeline $73.92 m
Nabi Pipeline $74.62 m
Cytokinetics Pipeline $ 75.17 m
Threshold Pharma $ 75.17 m
Tranzine pipeline $79.57 m
Peregrine pipeline $ 80.19 m
Aastrom Pipeline $83.04 mi
Cel Sci pipeline $93.08 m
Albany Molecular Research pipeline $ 94.06
INSMED Pipeline $94.37 m
Orexigen pipeline $100.98 m
Apricus Bioscience Pipeline $108.80 m
Gentium Pipeline $108.83 m
Zalicus pipeline $109.16 m
Repligen pipeline $109.19 m
Trancept pipeline $109.66 m
You will notice that only one or two companies have ever taken an FDA product to market and their pipelines don't even belong in the same post.
Conclusion BPAX belongs well over $1 per share at opening. Folks it doesn't get any simpler then this.
The market for Bio-t-gel was estimated at $1.2 billion in 2010
Market
My understanding is that Teva will pay Biosante $5 Million upon FDA approval and a 10% royalty on sales. Interestingly The new merger between Jazz and Azur pharma has heightened the profile of Elestrin as well. Biosante gave up some royalties for up front cash for Elestrin but may receive milestone payments of up to $140 million based on sales. AIS whose technology was used in the making Elestrin has been receiveing royalties. It will be interesting to see if Elestrin sales grow to the point of reaching milestone payments.
I wasn't criticizing you. I agree with you. I wanted people to notice they were bullish on Teva and Bio-t-gel approval reason #2.
In Fairness Seeking Alpha does have some ethical contributors
Look at reason #2
The Nanotech Revolution in Drug Delivery
Found this interesting post on the BPAX Yahoo board
The value of these nano-enabled
compounds will sky rocket, reaching $220 billion by 2015
Look at slide #4 under Key players and there is BPAX!!!!!
The Nanotech Revolution in Drug Delivery
Are you still thinking of selling???
Can't forecast revenue. But I read that Biosante gets $5 million upon approval and a 10% royalty on sales. As for maket share, I read somewhere (can't remember where) but Bio-T-Gel could become the the favorite due to the improve delivery method, some of the competition transfers testosterone to the sexual partner (many partners don't want this).
It appears that the partnership between Jazz and Azur could create some revenue for BPAX. As they focus on expanding the market for Elestrin.
According to the Jazz and Azur Partnership
• Significant growth opportunity driven by Elestrin , a topical gel ERT therapy
• Patents through 2022
• Revamped Elestrin promotion model in 2010 leveraging 51 sales representatives
If you look at page 12 of the slide presentation you will see that Elestrin is tracking in the right direction for future revenue growth.
I was originally sceptical, but if you look at the results of phase II trials as well as the Intrinsa trials that the Nutsyprofessor has researched. He has made a compelling argument a for something being out of whack with this placebo. It appears to have performed much better then any other placebo in the past. Sexual appetite is very subjetcive, but when they measured testosterone levels the placebo barely moved. Libigel won hands down. As I understand it, the Bloom trials proved that HSDD can be treated with a product designed for women.
I believe the criteria for inclusion and exclusion was set by the FDA or at least they exerted a lot of influence.
Since Viagra has developed a reacreational black market for perfomance enhancement,I wonder if the FDA or Bioasante wanted to measure this in the test as well, by including non-HSDD women in the trial (it was not the intended audience of this product). The safety trial criteria included post menopausal surgical or natural with HSDD diagnosis.
Efficacy
Inclusion Criteria:
•Must be between the ages of 30 to 65 years
•Must have undergone hysterectomy and bilateral salpingo-oophorectomy
Exclusion Criteria:
•A history of allergic reactions to androgens (oral or patch), topical alcohol, or any component of the formulation
•Any systemic skin diseases or local skin abnormalities in the area of application
•Diagnosed with another primary female sexual dysfunction (e.g., Sexual Aversion Disorder, Female Sexual Arousal Disorder).
•A medical condition that could affect or interfere with sexual function
•Using a systemic transdermal gel or cream estrogen therapy.
Results from the safety trials should come out in June 2012. This will produce a wealth of knowledge as well.
Safety
Inclusion Criteria:
Postmenopausal female subjects
•at least 50 years of age
•with at least two points of cardiovascular risk
•with a clinical diagnosis of HSDD.
Exclusion Criteria:
Subjects must not
•require treatment with anti-androgens, high-dose oral or injectable corticosteroids, tamoxifen or other selective estrogen receptor modulators,
•have used androgen therapy within 2 months of randomization,
•have a history of estrogen-dependent neoplasia or any gynecologic cancer,
•have a history of cancer of any kind in the past 10 years prior to randomization,
•have a history of malignant melanoma or a history of invasive cancer at any time,
•have a screening mammogram with any finding that requires follow up within 6 months of randomization,
•have a history of myocardial infarction, coronary revascularization or stroke within 12 months of randomization,
•have any medical condition associated with predicted survival of less than 3 years in the judgment of the Investigator.
It almost appears as they used the efficacy, extention and safety trials to cover as many bases as possible. The Safety results is really the prize. With good results they have a product, the post hoc analysis will determine how big the prize is going to be.
Personnaly I believe GVAX will be the product to have Biosante reach it's true potential. Libigel will just get them there faster.
Based on the Nutsyprofessor's analysis, those in the know realize that BPAX stock should presently be sitting in the $3 -$4 range up from $2.50 range prior to December 14, as the testosterone delivery method of Libigel was successfully proven. This moves the yards stick closer to the end zone.
FYI
It appears the extension trial was always part of the plan. You will notice it was first received November 4th, 2010 and updated October 4, 2011
ClinicalTrials.gov Id: NCT01235754
Study Title: Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
First Received: November 4, 2010
Last Updated: October 4, 2011
Extension Trial
Vince, I am not a day trader and would not benefit from full subscription, so I can not reply privately. In response to your inquiry, "When is the best time to invest in BPAX?" I do not have a crystal ball. Do your homework, you have to comfortable with what you are purchasing. Research all BPAX's products pipeline and it's diversity. In my honest opinion, the negative press in relation to Libigel and GVAX 2008 Phase III trial have created an opportunity that doesn't come around very often.
A special thanks to Yahoo's Nutsyprofessor and his/her supporting cast.
I have previously provided a number of financial reasons to stick with BPAX. Now I have taken the time to filter through much of the crap on the Yahoo BPAX message board to provide you the scientific reasoning that BPAX makes perfect sense. I strongly urge you to read the entire threads as there is very interesting information being shared and discussed.
NEW STUDY: LibiGel SIGNIFICANTLY LOWERS CHOLESTEROL
I HAVE THE ANSWER TO WHAT'S HAPPENING W/LIBIGEL
FURTHER PROOF - P&G's PH3 Trial w/Intrinsa
A really hope that BioSante knows what to look for in data
NO WAY BIOSANTE THIS DETAILED ANALYSIS...YET
Post-Hoc analyses - followed and WORST case scenario
Reasons to Own/Hold BioSante through 2012
I RECOMMEND NOT SELLING AT ALL - HERE'S WHY
Gvax
Emphasizing Jeff's point - PLUS SOMETHING BIG I MISSED BEFORE
Did you know Libigel is also being tested for cognitive improvement and for lowering cholesterol? It is not just a Female Viagra, as has been touted. It is all about the testosterone delivery method. It may be bigger then most of us imagined.
Enjoy the posted discussion.
Do the Math - Forget price per share. Market Cap evaluation truly shows where BPAX belongs.
In order to help with your own due diligence follow the link and see where BPAX sits in the list of 311 Biotech and Drug companies. Follow the links to the companies BPAX is competing against and look at their products and pipeline. For those who aren't already sold on BPAX it will be your AHA! momment.
Biotech and Drug companies
I have provided a list of companies with their Market Cap, Annual Revenue and Annual Net Income. In my honest opinion BPAX arguably should have a greater market cap then most if not all the listed companies,as BPAX is a much more diversified company.
Company = Market Cap / Annual Revenue / Annual Net Income ($ MILLION)
Biosante = 59.37 / 2.47 / -46.20
YM Bioscience = 189.07 / 1.01 / -40.04
Cell therapeutics = 221.68 / 0.32 / -147.56
Cadence Pharma = 255.73 / 0 / -56.54
Corcept Thearap. = 264.49 / 0 / -25.97
Navidea Biopharma = 265.36 / 10.7 / -58.09
Anthera Pharma = 286.76 / 0 / -40.41
Progenics Pharma = 287.32 / 7.35 / -69.72
Raptor Pharma = 299.54 / 0 / -37.19
Chelsea Therap. = 312.95 / 0 / -37.33
Clovis Oncology = 314.99 / 0 / -37.83
ZIOPHARM Oncology = 349.10 / 0 / -32.67
MannKind Corp. = 359.87 / 0.9 / -170.56
Lexicon Pharma = 493.01 / 4.91 / -101.78
Softballdaddy, I am not a subscribed member(yet)and not a day trader. Can't reply privately but thanks for the heads up.
Added value presently Azur only has US rights to Elestrin and Teva presently only has US rights to Bio-T-Gel.
Penny..., though the post you linked to may been authored by a lawyer. I am certain that the name John A. Seuthem (Sue Them) is fictitious.
To all those concerned by the lack of insider trading
Biosante's Corporate Governance & Code of Ethics prevent trading in times like this. Remember they are trying to obtain FDA approval. You don't want the company's ethics coming into question.
Code of Ethics
For those wanting to understand the science behind the clinical trials. I strongly recommend looking up all the post by the Nutsyprofessor on the Yahoo Bpax message board. He/she definitely reafirms my faith in Libigel the product.
Best time to consider long term investing in Biosante
At theses share prices the upside is astronomical. I did a little research on GVAX. Hope this provides more perspective. Elestrin, Libigel, Bio-T-Gel all offer quicker revenue opportunities in the world of drug development. However, the Holy Grail for Biosante is the cancer vaccines. The revenues generated from the former drugs will assist in finding the Grail.
Cancer vaccines are gaining much attention as shown on Dr OZ and other news shows.
Dr Oz Pancreatic Cancer Vaccine
Interestingly, Dr. Oz asked Dr. Jaffee, if this vaccine can be a game changer for other cancers as well, and Dr. Jaffie said that this approach is being tested in breast cancer patients, prostate cancer patients, melanoma, colon cancer patients and others
Biosante’s Cancer Vaccine Pipeline
For those wishing to learn more about Dr. Jaffee and the work being done with GVAX at John Hopkins, I have provided the following link.
Dr. Jaffee
Now Biosante has leveraged the orphan drug designation to further the research and development. Partnering with Aduro Bio Tech on the Phase II trials for pancreatic cancer - estimated completion October 2014
Trial 1
Trial 2
This provides a template for future trial development. I believe this trial partnership will be the first of many in relation to GVAX .
Rewards for patience.
I have attached a summary of the Cell Genesys– Takeda GVAX $320 Million licensing agreement to demonstrate the potential financial rewards when phase III trials are approved.
Cell Genesys– Takeda
Since GVAX appears usable in multiple forms of cancer the potential for multiple licensing opportunities is very enticing.
The beauty of GVAX is that unlike Provenge,the first FDA approved cancer vaccine, it can be mass produced and delivered in an more timely fashion. Provenge presently goes for $93,000 a pop. Provenge is like a designer drug, it is made for the specific patient. The mass production of GVAX allows for a higher profit margin while coming in at a significantly lower price. Which do you think HMOs and Medicare would favor? The ability to apply GVAX to other forms of cancer, as mentioned earlier, will further drive down manufacturing costs and increase profit margins.
Don't sell without viewing! - Catty, thanks for thew ords of encouragement. Everyone would be well advised to view the following discussion strings at BPAX Yahoo Message board. It plausibly explains what is happening and the silence from the company.
I HAVE THE ANSWER TO WHAT'S HAPPENING W/LIBIGEL
2/14/2012 (BPAX) faces FDA decision on Bio-T-Gel
The Nutsyprofessor has them hopping and even rubmitted a response to your post, clarifying what SIMES stated.
Nutsyprofessor response
The Nutsyprofessor is getting a following on other boards as well. It is shaping up to be fun week.
An excellent post from the Nutsyprofessor of the Yahoo BPAX message board. I only wish I could understand it all.
I HAVE THE ANSWER TO WHAT'S HAPPENING W/LIBIGEL!!!!
This is critical people but you have to follow me here and dig deep down into these details and try to follow along.
The first thing you need to do is to read the, "VALIDATION OF THE INVENTORY OF SEXUAL EVENTS AND DESIRE (ISED) DIARY", (see link); this is the whole key to what's going on between the BLOOM trials and this final extension trial and Simes comments that Biosante is reviewing in detail some data subsets and such.
VALIDATION OF THE INVENTORY OF SEXUAL EVENTS AND DESIRE
The key is that the women in the BLOOM trials were radomly assigned to the placebo and treatment arms, MEANING, they have NOT YET BEEN SEPERATED BETWEEN THOSE WITH HSDD AND THOSE W/OUT HSDD!!!! That was the whole purpose of using this FDA approved...VALIDATION OF THE INVENTORY OF SEXUAL EVENTS AND DESIRE (ISED) DIARY!!!! As you can see from the above link, this diary was tested and proved for this whole purpose:
""The BIOS-VAL-002 study was designed
to evaluate the Inventory of Sexual Events and Desire (ISED) event diary for discriminate validity between subjects
with HSDD and subjects without female sexual dysfunction (No FSD).""
So how does this now tie in with the final PH3 extension trial? SIMPLE: it's all in the EXCLUSION CRITERIA!!! As per the extension trial's indicated exclusion criteria: "Any condition (including a change in sexual or relationship history) that would make the subject unsuitable for participation in the trial in the opinion of the Investigator", this means that the trial investigators will now use the, "INVENTORY OF SEXUAL EVENTS AND DESIRE (ISED) DIARY"...to EXCLUDE the woman that have NO HSDD!!!! Once this is accomplished the placebo will no doubt show LESS efficacy than the treament arm!!! It's all very clear to me now how these series of trials are being conducted AND why this final extension trial is so important.
Trial extention
I am now more convienced than ever that LibiGel is still alive and well.
Libigel’s Testosterone Play?
Firstly, I want to thank those who welcomed me to the board.
I have also found the following information for your consideration.
Most of you are aware of the results released December 14th, 2011 The result of the testosterone were never in doubt as shown below.
BioSante Pharmaceuticals Announces Results from LibiGel® Efficacy Trials
Excerpt from above article
Importantly, and as seen in previous pharmacokinetic data, the LibiGel groups in both trials showed an increase in free testosterone levels compared to baseline and placebo. In BLOOM-1 mean free testosterone at baseline was approximately 1.19 pg/ml and 1.10 pg/ml in the placebo and LibiGel groups, respectively. In month six of the trial, free testosterone levels were approximately 1.35 pg/ml and 4.01 pg/ml in the placebo and LibiGel groups, respectively. In BLOOM-2 mean free testosterone at baseline was approximately 1.06 pg/ml and 1.19 pg/ml in the placebo and LibiGel group, respectively. In month six of the trial, free testosterone levels were approximately 1.09 pg/ml and 3.70 pg/ml in the placebo and LibiGel groups, respectively.
The trials demonstrated that LibiGel was generally well tolerated with a safety profile that appears to be comparable to the placebo. Remember the Bloom 1 and 2 trials increased sexual satisfaction was subjective and recorded in a diary allowing greater chance of a placebo effect. The testosterone levels are clinical and concrete.
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFOinterviews.com, Published - March 11, 2011
Excerpt from above article
CEOCFO: What is the market opportunity for LibiGel?
Mr. Simes: There are different ways to look at the market. The erectile dysfunction market in the U.S., which is the market for Viagra, Levitra, and Cialis, is about $2 billion a year. Based on publications on women’s self-reporting of how many women suffer from low sexual desire, or low sexual activity, we believe the market for women is at least $2 billion. However, there is another very important consideration. Last year in the U.S., there were 4 million testosterone prescriptions, written off-label by physicians for women. That is, they are using men’s testosterone or they are using other products that are not FDA-approved to treat the condition. In any event, doctors already are prescribing and women already are using testosterone for this indication, and the 4 million depending on the pricing would result in a $1 to $2 billion potential for LibiGel. Now the question is why do we need LibiGel? Those other products are not FDA-approved or clinically tested, so the safety has not been proven and most importantly there is no way of knowing what the effective dose is. Therefore, in our primary research, doctors tell us that, if and when LibiGel is approved, they will switch about 96% of those women using testosterone today to LibiGel. That represents well over a $1 billion opportunity for us.
CEOCFO: In closing, why should potential investors choose BioSante Pharmaceuticals?
Mr. Simes: BioSante is a very interesting opportunity and is a company on the leading edge of a very important unmet medical need. Female sexual dysfunction is a very critical issue and again I will repeat, thirteen years after Viagra was approved for men, women still don’t have an option for their sexual health. To the extent that women want to be treated, we think a product should be available. It is all about choice for women. We are developing LibiGel, which is in late stage, Phase III clinical development with an approval on the horizon. We believe the upside for our stockholders is dramatic. We have the money in the bank to implement the plan as I have described, as well as the people to take this product through to an FDA approval. They have a proven track record as evidenced by our Elestrin approval. LibiGel is being dealt with by the same division at the FDA, The Division of Reproductive and Urologic Products, as was Elestrin. In summary, we believe BioSante is well positioned for increasing value for our stockholders.
Menopause and Testosterone
Excerpt from above article
Testosterone is an important factor in women's health before and after menopause. Testosterone provides several benefits to women:
• improves relief of vasomotor symptoms of menopause
• increases energy levels
• enhances of feelings of well-being
• decreases breast tenderness
• improves sexual desire
• increases sexual sensitivity
• increases the frequency of coitus
• enhances orgasm
Conclusion:
Biosante Plan B is going from "Viagra for women" to a testosterone designed for women which has been clinically tested and FDA with reduced side effects. Not the home run of Female Viagra but a solid double. Patent until 2022 with potentially 4 + million prescriptions per year (US only) and an aging population = potential > $8 billion in sales up to 2022.
A little perspective
I am new to the board but it has been fun reading the posts
Here are some additional facts that I uncovered which you may wish to consider
Feb 2010 (don’t know where they sit today) BPAX was ranked 15th out of 67 biotech companies for the quality of their patent portfolio. I have attached the top 10 listed on the Patent Scorecard as published by The Patent Board.
1 Roche Holding Ltd
2 Johnson & Johnson
3 Amgen Inc
4 Biogen Idec
5 Isis Pharmaceuticals
6 Merck KGaA
7 Bristol-Myers Squibb
8 Human Genome Sciences
9 Alnylam Pharmaceuticals
10 Sanofi
With respect to the a/n Biotechnology top 10 in patent quality only Isis Pharmaceuticals ($719 million Market Value & -$.079 EPS ) and Alnylam Pharmaceuticals ($351 million Market Value & -$1.18 EPS ) have a sub $1 billion market value. A quick look at product development and pipelines, it appears to me that solely based on these factors (Libigel aside) the market value should sit somewhere between the two, as BPAX appears to have a more developed portfolio with Phase 3 trials and approvals then Alnylam Pharmaceuticals. Yet, BPAX today only has a market value of $56 million and an EPS of -$0.69
BPAX has equity stake in external companies
19.9 % ownership of Cold Genesis (Private Company) who are presently conducting phase II and III trials
Transitional Cell Carcinoma Biological: CG0070 adenovirus vector
Phase II
Bladder Cancer Other: Control Arm: Triple Choice Phase III
16 % ownership of Ceregene, Inc. (Private Company) who have the following pipeline
Pakinsinson Deaease Phase II trials
Alzhiener's Disease Phase II trials
This is all in addition to Biosante’s pipleine Elestrin (approved) Libigel, Bio-T-Gel, The Pill Plus.
Cancer research is expensive however BPAX has found a way to partner and entice other companies to further their research (i.e., GVAX) Some complain about not getting much in return for allowing the use of their vaccines. I believe practically giving it way will prove fruitful in the end. More partners playing with their vaccines will speed up it’s time to market while reducing associated costs. Monetizing came later for Facebook the same could happen with BPAX.
In all this is not a one product wonder,by all accounts it looks like BPAX wants to play with the big boys or girls. The best $56 million company I have ever seen.